Introduction
Geographic Atrophy (GA) is a retinal disease that affects eight million people worldwide, being most prevalent in elderly in developed countries. The disease is slow progressive. Without intervention, many GA patients may eventually develop severe visual loss and go blind in their lifetime. Despite several natural history studies 1, 2, 3 , the long-term disease burden and potential benefits of treating GA remain unclear.
The aim of this work was to simulate the long-term impact of GA on visual disability and blindness, and the expected benefits of intervention. A microsimulation model was developed using Excel Visual Basic Application (VBA) to forecast: 1) the longterm risk of becoming visually disabled and blind among subjects with diagnosed GA and 2) the impact of treating GA with a hypothetical intervention.
Results

Figure 3.
Among subjects diagnosed with GA, the risk of becoming blind during their lifetime increases with:
• The younger age at diagnosis (Figure 3a) • The worse VA at diagnosis (Figure 3b) • The faster rate of VA decline (Figure 3c) 
Methodology
Model Structure:
A micro-simulation model was developed using available natural history data on rate of vision loss among subjects with diagnosed GA. Subjects' health states were characterized based on visual acuity (VA) in the better-seeing eye as follows: Subjects with GA progress through the visual health states following the rate of VA decline per year from AREDS study 3 . The subjects can encounter death during any one of the visual health states. Time horizon of the model is lifetime.
Model Inputs:
Univariate sensitivity analysis was performed for age at GA diagnosis, VA at diagnosis, and rate of VA loss following the basecase and range listed in Table 1 . The impact of treatment was evaluated with target efficacy of 25%, 50%, 75% and 100% on reduction in the baseline rate of VA loss (3.6 letters loss/ year).
The model outputs:
• Lifetime years spent with visual disability (VA ≤20/80 ->20/200) and blindness (VA ≤20/200) • Time to event curves for visual disability and blindness Limitations  The simulation model utilizes the general population life expectancy table to estimate the residual lifetimes for subjects with GA. The lifetime disease burden, therefore, may be overestimated. In future, the GA specific life expectancy table will be used to better capture the benefits of early intervention.  The current model captures expected benefit of treatment in terms of reduction in years with blindness. The future model will incorporate the health state utilities and costs associated with visual states to model the quality adjusted life year gains and cost effectiveness of intervention.  The current model simulated the disease burden based on VA on better-seeing eye (i.e. worst case scenario). Distribution of visual loss at the eye level in GA subjects needs to be better understood and incorporated into the future model.
Conclusions
The simulation model based on natural history of GA progression showed that GA would cause significant burden in terms of visual disability and blindness and effective treatment can reduce that burden. For subjects under treatment, the reduction in years of blindness improves at an increasing rate in treatment efficacy.
Simulation model is a useful approach to quantify the disease burden and benefits of intervention and aids in addressing unmet medical needs and drug development.
Results
Figure 1.
 The simulation model estimated that without treatment, subjects with GA on average spend four years with visual disability and 8 years with blindness during their lifetime.
 Given a hypothetical treatment with efficacy of 50% (preventing 1.8 letter loss per year), the subjects spend six years with visual disability and 4 years with blindness ( Figure 1 ).
Figure 2.
 Without treatment, estimated 91.8% of subjects develop visual disability by year 10 after diagnosis.
 Given a hypothetical treatment with efficacy of 50%, approximately 77.6% of subjects develop visual disability by year 10 (Figure 2a) .  Without treatment, 62.4% of subjects become blind at year 10 after diagnosis (Figure 2b ).
 The risk of becoming blind is reduced to 18.4% by an intervention with a hypothetical efficacy of 50%.  For subjects diagnosed with GA, hypothetical treatment benefit is significantly driven by level of efficacy (Figure 4 ).
-While other variables were kept in basecase (table 1) , a 25% efficacy (preventing 0.9 letter loss per year) reduces time spent with blindness by one year while a 75% efficacy (preventing 2.7 letter loss per year) reduces time spent with blindness by six years. 
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